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Abstract
Background There is a close association between frailty and cognitive impairment. However, the underlying contribution of
sarcopenia to the development of cognitive impairment is unclear. We investigated the possible association between muscle
mass decline and cognitive impairment in a cross-sectional study of 1518 subjects aged 55 years or above. We also evaluated
arterial stiffness and white matter hyperintensities (WMHs) as possible underlying mechanisms for this association.
Methods Two sarcopenic indices were measured: thigh muscle cross-sectional area (CSA; calculated by computed tomogra-
phy) and skeletal muscle mass (bioelectric impedance). Muscle mass decline was defined as either the bottom 10% or 20% of
participants for each sex. Cognitive function was assessed using the Touch Panel-type Dementia Assessment Scale, and
brachial–ankle pulse wave velocity was measured as an index of arterial stiffness.
Results Both sarcopenic indices were modestly but significantly associated with brachial–ankle pulse wave velocity in male
and female subjects. The presence of WMHs was significantly associated with low thigh muscle CSA in men and with low skel-
etal muscle mass in women. The Touch Panel-type Dementia Assessment Scale score was modestly but significantly and pos-
itively associated with thigh muscle CSA in men and skeletal muscle mass in women. Muscle mass decline in the bottom 10%
of participants on both sarcopenic indices was significantly and independently related to cognitive impairment in women.
Conclusions Lower sarcopenic indices are significantly related to lower cognitive scores. Arterial stiffness and WMHs could
account, at least in part, for this association.
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Introduction
Cognitive function in elderly people is highly related to phys-
ical function.1 Recently, several studies have reported an as-
sociation between lower gait speed and cognitive decline in
mild cognitive impairment,2 as well as dementia.3,4 Verghese
et al.5 proposed motoric cognitive risk syndrome, character-
ized by a slow gait speed and cognitive complaints, as a newly
described pre-dementia syndrome.
Frailty is a condition that is characterized by progression of
physiological decline in elderly people and is prodromal for
dependence, institutionalization, and even death.1 Slow gait
speed and lower hand grip strength are among the five mea-
sures of frailty that were proposed by Fried et al.6 and are
also criteria for the diagnosis of sarcopenia.7 Sarcopenia is
an age-related decline in muscle mass and strength and a ma-
jor component of frailty.
We and others have shown that sarcopenia is associated
with increased arterial stiffness.8,9 Several studies, including
meta-analyses, have reported close associations between ar-
terial stiffness and cognitive impairment.10–13 Although the
precise mechanisms have not been determined, arterial
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stiffness has been associated with brain white matter
hyperintensities (WMHs),11 a well-demonstrated risk factor
for cognitive decline.14 These findings suggest that the effect
of sarcopenia on cognitive impairment may be mediated by
arterial stiffness and WMHs. However, results from studies
that have evaluated the association between sarcopenia
and cognitive impairment in a general population are incon-
clusive.15–19 Furthermore, no studies have evaluated the un-
derling mechanisms linking sarcopenia and cognitive
impairment.
We performed a cross-sectional study looking for possible
associations between two sarcopenic indices and cognitive
impairment, taking into account arterial stiffness and WMHs
as possible pathological mechanisms in participants of the
Japan Shimanami Health Promoting Program study.
Methods
Study subjects
The study subjects were 1518 apparently healthy individuals
aged 55 years or above who were consecutive participants
in the medical checkup programme at Ehime University Hos-
pital Anti-aging Center from February 2006 to December
2015. This medical check-up is provided to general residents
of Ehime Prefecture, Japan, and is specifically designed to
evaluate ageing-related disorders, including atherosclerosis,
cardiovascular disease, physical function, and mild cognitive
impairment.9,20–22 Of the 1691 consecutive patients who
were initially approached, 1518 (mean age, 67.9 ± 6.8 years)
gave written consent for all procedures and had no history of
symptomatic cardiovascular events, including peripheral arte-
rial disease, stroke, coronary heart disease, and congestive
heart failure. The present study was part of a series of the
Japan Shimanami Health Promoting Program study, which
was approved by the Ethics Committee of Ehime University
Graduate School of Medicine.9,20–22
Measurement of sarcopenia-related indices
Thigh muscle cross-sectional area
Thigh muscle cross-sectional area (CSA) was measured using
computed tomography (CT) (LightSpeed VCT; GE Healthcare,
Tokyo, Japan). Images were created at the mid-thigh, defined
as the mid-point between the inguinal crease and the proxi-
mal pole of the patella.9,21 Muscle CSA (cm2) was computed
using an attenuation range of 0–100 Hounsfield units, and
this excluded intramuscular fat.
Bioelectric impedance analysis
The total skeletal muscle ratio was evaluated by the bioelec-
trical impedance method using a commercially available body
composition analyser (body scan HBF-701; Omron Healthcare
Co. Ltd., Kyoto, Japan). The manufacturer’s built-in,
preprogrammed algorithms were used to calculate the per-
centage of skeletal muscle. Skeletal muscle mass (in kg) was
calculated as ‘body weight (kg) * skeletal muscle
percentage’.20,21
Participants scoring in the bottom 20 and 10% on each
sarcopenic index were defined as having muscle mass de-
cline, stratified separately by sex.
Measurement of visceral fat area
Visceral fat area was measured using CT at the level of the
umbilicus, with attenuation in the range of 150–50 Houns-
field units. Images were obtained with a minimal slice width
of 5 mm and were analysed using OsiriX software (OsiriX
Foundation, Geneva, Switzerland).20,21 Thigh muscle CSA
and visceral fat area measurements were only available for
1505 subjects (603 men and 902 women).
Magnetic resonance imaging and assessment of
white matter hyperintensities
The presence of WMHs, including periventricular
hyperintensity (PVH), and deep subcortical white matter
hyperintensity (DSWMH), was evaluated by brain magnetic
resonance imaging (MRI) with a 3-tesla scanner (Signa Excite
3.0T; GE Healthcare, Milwaukee, WI). Details of brain MRI
have been described elsewhere.22 Hyperintensities depicted
on T2-weighted FLAIR images in contact with the ventricular
wall and located in the subcortical region were defined as
PVH and DSWMH, respectively. PVH was further classified
into five grades in accordance with Japanese guidelines as fol-
lows23: grade 0, absent or only a ‘rim’; grade 1, limited lesion-
like ‘caps’; grade 2, irregular ‘halo’; grade 3, irregular margins
and extension into the deep white matter; and grade 4, ex-
tension into the deep white matter and subcortical portion.
DSWMH was also classified into five grades as follows23:
grade 0, absent; grade 1, ≤3 mm small foci and regular mar-
gins; grade 2, ≥3 mm large foci; grade 3, diffusely confluent;
and grade 4, extensive changes in the white matter. The pres-
ence of WMHs was defined as PVH grade ≥ 2 and/or DSWMH
grade ≥ 3. Images were analysed by two neurologists without
clinical information on the subjects. Images were analysed
using OsiriX software (http://www. osirix-viewer.com).
Assessment of cognitive function
Cognitive impairment was assessed using the Touch Panel-
type Dementia Assessment Scale (TDAS), which was specifi-
cally designed to rate cognitive dysfunction quickly and
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without the need for a special rater.22 This test battery
consists of the following four tasks, which were performed
in a fixed order: a three-word memory test for assessing im-
mediate memory, a temporal orientation test, a three-
dimensional visual–spatial perception test, and a delayed
recall test to assess short-term memory.24 The TDAS provides
for a maximum score of 15 points, and a score of 12 or less
was suggested as indicative of cognitive impairment in a
previous study.24 Details of this rating system have been de-
scribed elsewhere.24
Pulse wave velocity
Pulse wave velocity (PWV) was measured using a volume-
plethysmograph (PWV/ankle brachial index; Omron
Healthcare Co. Ltd., Kyoto, Japan). A detailed explanation of
this device, as well as the validity and reproducibility of its
measurements, has been provided elsewhere.25 Brachial-to-
ankle PWV (baPWV) was calculated from the time interval be-
tween the wave fronts of the brachial and ankle waveforms
(ΔTba) and the path length from the brachium to the ankle.
The path length from the suprasternal notch to the brachium
(Lb) or ankle (La) was obtained using the following formulae:
Lb = 0.2195 × height + 2.0734; La = 0.8129 × height + 12.328.
The baPWV was then obtained using the following equation:
(La  Lb)/ΔTba. The intra-measurement reproducibility of
baPWV in our laboratory was 2.1 ± 1.8%, and between mea-
surements, the reproducibility was 2.2 ± 1.5%.
Evaluation of risk factors
Lifestyle, medical history, and prescribed drugs were evalu-
ated by questionnaire. Anthropometric measurements were
performed by a trained nurse. Venous blood was collected
in the morning after ≥11 h fasting for measurement of serum
lipid and plasma glucose concentrations. Blood pressure was
measured with oscillometric device (HEM-9000AI; Omron
Healthcare Co., Ltd) in a sitting position after at least 5 min
of rest.
Statistical analysis
Because men and women have important physiological dif-
ferences, all statistical analyses were performed separately
for each sex. Differences in numeric variables were assessed
with an analysis of variance, with Tukey’s correction for mul-
tiple comparisons applied. Frequency differences were
assessed by the χ2 test and logistic regression analyses. Co-
variate adjusted analysis was performed by multiple linear re-
gression analyses and logistic regression analyses with
possible independent parameters including age, body mass
index, systolic blood pressure, total cholesterol, high-density
lipoprotein cholesterol, triglyceride, fasting blood glucose,
immune-reactive insulin, current smoking, alcohol consump-
tion, physical activity, use of antihypertensive drugs, anti-
dyslipidemic drugs, anti-diabetic medication, baPWV, and
the presence of WMHs. Statistical analyses were conducted
using commercially available statistical software (JMP version
10.0.2; SAS Institute Inc., Cary, NC), with P < 0.05 considered
statistically significant.
Results
Clinical characteristics of the study population divided by the
TDAS score are shown in Table 1 and Table S1. Thigh muscle
CSA was significantly lower in men with lower TDAS scores,
and skeletal muscle mass was significantly and positively
associated with TDAS score in both men and women.
Brachial-ankle PWV was significantly associated with TDAS
score in both men and women.
Sarcopenic indices and pulse wave velocity
In both men and women, baPWV was modestly but signifi-
cantly and negatively associated with thigh muscle CSA
(men: r = 0.24, P < 0.0001; women: r = 0.12,
P = 0.0001) and with skeletal muscle mass (men: r = 0.24,
P < 0.0001; women: r = 0.23, P < 0.0001). Furthermore,
as shown in Figure 1, the relationships between sarcopenic
indices and baPWV were not linear. The reduction in scores
on sarcopenic indices associated with increases in baPWV
reached a plateau at the second tertile in both men and
women.
Sarcopenic indices and white matter
hyperintensities
Figure 2 shows thigh muscle CSA and skeletal muscle mass in
the three groups split into PVH and DSWMH grades. In both
men and women, both sarcopenia indices were significantly
and negatively associated with WMH grades, except for thigh
muscle CSA and DSWMH grade in women.
Odds ratios of sarcopenic indices for the presence of
WMHs are shown in Table 2. Even after adjustment for possi-
ble confounding parameters (adjustment 1), low thigh muscle
CSA was significantly associated with WMHs in men, while
low skeletal muscle mass was significantly related to WMHs
in women. Further adjustment for baPWV (adjustment 2)
eliminated the significant association in men but not in
women.
Muscle mass and cognitive impairment 559
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Sarcopenic indices and cognitive scores
Touch Panel-type Dementia Assessment Scale scores (a con-
tinuous variable) showed a modest but significant positive as-
sociation with thigh muscle CSA (men: r = 0.16, P < 0.0001;
women: r = 0.08, P = 0.016), and skeletal muscle mass (men:
r = 0.15, P = 0.0002; women: r = 0.14, P < 0.0001) (Figure 3).
Multiple regression analyses showed that thigh muscle
CSA was significantly positively related to TDAS score in
men independently of other possible confounding parame-
ters (S2), while in women, skeletal muscle mass was signifi-
cantly and independently associated with TDAS score (S3).
Further adjustment with baPWV and WMHs eliminated the
association between thigh muscle CSA and TDAS score in
men, but not the association between skeletal muscle mass
and TDAS score in women.
Muscle mass decline and cognitive impairment
Odds ratios of muscle mass decline for the presence of cogni-
tive impairment are shown in Table 3. Muscle mass decline
(defined as the bottom 10% of the studied population) was
significantly associated with cognitive impairment in women,
even after adjustment for confounding parameters including
baPWV and WMHs. However, muscle mass decline in men
was not associated with cognitive impairment.
Discussion
The present study showed that sarcopenic indices were sig-
nificantly associated with arterial stiffness, brain WMHs,
and cognitive test scores. We also observed that subjects
with muscle mass decline, defined as the bottom 10% of
the studied population, had cognitive impairment in the
middle-aged to elderly female population. These findings in-
dicate that sarcopenia, a component of frailty, plays an im-
portant role in cognitive decline in the general population.
Several cross-sectional and longitudinal studies have dem-
onstrated a close association between frailty and cognitive im-
pairment.1 Other possible frailty-related symptoms, such as
orthostatic hypotension, are also associated with cognitive
dysfunction and dementia.26 We previously showed that de-
creased one-leg standing time was significantly related to
Figure 1 Tertiles of brachial-ankle pulse wave velocity (baWV) and thigh muscle cross sectional area (upper) and skeletal muscle mass [bottom]. For
men and women, the lowest tertile of baPWV scores had the highest thigh muscle cross-sectional area (CSA) and skeletal muscle mass. Values are
mean ± SEM. *P < 0.05 vs. first tertile.
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Figure 2 White matter hyperintensity and sarcopenic indices. Two indices for sarcopenia are shown, split by periventricular hyperintensity (PVH) and
deep subcortical white matter hyperintensity (DSWMH). The numbers in the columns indicate the number of subjects. Values are mean ± SEM.
*P < 0.05 vs. first tertile. †P < 0.05 vs. second tertile.
Table 2 Odds ratios for the presence of white matter hyperintensities
Parameters for sarcopenia
Men Women
Odds ratio 95% CI P Odds ratio 95% CI P
Thigh muscle CSA/1 SD n 603 902
No adjustment 0.63 0.52–0.77 <.0001 0.81 0.69–0.96 .015
Adjustment 1 0.74 0.54–099 .046 0.88 0.70–1.11 .29
Adjustment 2 0.75 0.55–1.01 .059 0.89 0.70–1.14 .30
Skeletal muscle mass/1 SD n 609 909
No adjustment 0.65 0.53–0.79 <.0001 0.67 0.56–0.80 <.0001
Adjustment 1 0.80 0.60–1.08 .15 0.73 0.57–0.93 .01
Adjustment 2 0.82 0.60–1.11 .20 0.73 0.57–0.94 .01
CI, confidence interval.
Odds ratios for the presence of white mater hyperintensities, stratified by increase in sarcopenic indices (by 1 SD).
Adjustment 1: adjusted for age, body mass index, systolic blood pressure, triglyceride levels, total cholesterol levels, high-density lipopro-
tein cholesterol levels, glucose levels, immunoreactive insulin levels, use of antihypertensive drugs, antidyslipidemic drugs, antidiabetic
drugs, current smoking, alcohol intake, physical activity (1 + 2 + 3 + 4).
Adjustment 2: Further adjustment for brachial–ankle pulse wave velocity.
White matter hyperintensity was defined as periventricular hyperintensity grade ≥ 2 and/or deep subcortical white matter hyperintensity
grade ≥ 3. One SD of thigh muscle CSA was 18.92 cm2 for men and 13.49 cm2 for women, and that of skeletal muscle mass was 3.14 kg
for men and 2.02 kg for women.
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Figure 3 Scatter plots showing relationship between touch panel-type dementia assessment scale (TDAS) score and thigh muscle cross-sectional area
(CSA) (top) and skeletal muscle mass (bottom) in men and women.
Table 3 Odds ratios of sarcopenia for the presence of cognitive impairment
Men Women
Sarcopenia definition Model Odds ratio 95% CI P Odds ratio 95% CI P
Thigh muscle CSA n 603 902
Bottom 20% No adjustment 2.57 1.36–4.74 0.004 1.56 0.89–2.65 0.12
Adjustment 1 1.75 0.75–4.03 0.19 1.19 0.61–2.24 0.61
Adjustment 2 1.69 0.72–3.91 0.23 1.13 0.57–2.15 0.72
*Bottom 10% No adjustment 1.84 0.77–3.95 0.16 2.92 1.55–5.24 0.001
Adjustment 1 0.87 0.30–2.32 0.79 2.58 1.21–5.33 0.015
Adjustment 2 0.81 0.28–2.18 0.69 2.58 1.18–5.43 0.02
Skeletal muscle mass n 609 909
Bottom 20% No adjustment 2.05 1.07–3.81 0.03 2.12 1.24–3.52 0.007
Adjustment 1 1.48 0.67–3.23 0.33 1.65 0.87–3.07 0.13
Adjustment 2 1.55 0.81–2.90 0.18 1.54 0.81–2.90 0.18
*Bottom 10% No adjustment 2.20 0.96–4.60 0.06 2.95 1.57–5.29 0.001
Adjustment 1 1.43 0.53–3.58 0.47 2.50 1.16–5.23 0.02
Adjustment 2 1.46 0.54–3.69 0.44 2.38 1.09–5.04 0.03
CI, confidence interval.
*Subjects with a muscle mass in the top 80% were used as controls.
Adjustment 1: adjusted for age, body mass index, systolic blood pressure, triglyceride levels, total cholesterol levels, high-density lipopro-
tein cholesterol levels, glucose levels, immunoreactive insulin levels, use of antihypertensive drugs, antidyslipidemic drugs, antidiabetic
drugs, current smoking, alcohol intake, and physical activity.
Adjustment 2: further adjusted for brachial–ankle pulse wave velocity and the presence of white matter hyperintensity. White matter
hyperintensity was defined as periventricular hyperintensity grade ≥2 and/or deep subcortical white matter hyperintensity grade ≥3.
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cognitive dysfunction.22 Rockwood’s model of frailty even al-
lows poor cognition to be included as one of the possible com-
ponents of frailty,27 leading to the proposal of the condition
known as cognitive frailty.28 However, specific factors of frailty
associated with cognitive decline are not fully understood.
Sarcopenia, one of the main components of frailty, may
underlay the connection between frailty and cognitive im-
pairment. However, studies of the association between
sarcopenia and dementia are inconclusive.15–19 In a large co-
hort of 7105 elderly women, body composition, low fat mass,
and low fat-free soft mass were significantly associated with
cognitive impairment after adjustment for multiple possible
confounding variables.15 In the EIDOS cohort, cognitive im-
pairment was significantly associated with slow walking
speed and low hand grip strength, but sarcopenic parameters
obtained from dual-energy X-ray absorptiometry were not re-
lated to cognitive impairment.16 Longitudinal findings are
also not conclusive. In a 1 year follow up of 131 Japanese el-
derly subjects, sarcopenia was associated with a larger de-
cline in MMSE scores.18 However, the longitudinal EPIDOS–
Toulouse study reported that decreased muscle mass and
walking speeds were not associated with cognitive decline
in 181 elderly women.19 These findings suggest that differ-
ences in the methods used to evaluate sarcopenia, the defini-
tion of sarcopenia, and the studied population could underlie
the inter-study inconsistency.29
In the present study, we corroborated previous findings
providing insight into the underlying mechanisms linking
sarcopenia and cognitive decline. Arterial stiffness has been
demonstrated as a risk factor for cognitive decline.10,11 We
have demonstrated that muscle mass showed a significant
but modest association with baPWV, which may explain the
non-linear relationship between muscle mass decline and
higher baPWV. Because arterial stiffness has also been iden-
tified as an underlying mechanism for brain small vessel dis-
ease, we further evaluated the possible association
between sarcopenic indices and WMHs, which is also thought
to be related to cognitive impairment.14
Several studies, including meta-analyses, report that arte-
rial stiffness is a risk factor for cognitive impairment.10–13 Re-
cent observations in the Framingham cohort suggest that
aortic stiffness is associated with white-matter injury and
cognitive function in midlife,13 consistent with our hypothe-
ses. In the present study, we observed that sarcopenic indices
were also related to WMHs, even though the association var-
ied between men and women, as well as between sarcopenic
parameters. Thigh muscle CSA was significantly associated
with WMHs in men, but co-varying for baPWV eliminated
the significance of this association. However, in women, skel-
etal muscle mass was significantly associated with WMHs,
and interestingly, this association persisted even after correc-
tion for baPWV. This finding suggests that other, as yet un-
known mechanisms, may also link WMHs and sarcopenic
indices in women.
We observed that sarcopenic indices were marginally asso-
ciated with TDAS scores in men, even after adjustment for sev-
eral possible confounding parameters. However, muscle mass
decline in the bottom 10 and 20% of subjects was not related
to cognitive impairment. However, in women, muscle mass
decline in the bottom 10% of subjects was significantly related
to cognitive impairment, even after adjustment for baPWV
and WMHs. Although the precise explanations for the differ-
ence between men and women observed in the present study
have not yet been elucidated, the arbitrary definition of mus-
cle mass decline (bottom 10 and 20%) might account for this
observation. In multiple regression analyses, baPWVwas inde-
pendently associated with TDAS score in women, while
WMHs, but not baPWV, was a significant determinant of TDAS
score in men (Table S1). These findings indicate that the
underlying pathology relating to cognitive decline may differ
between men and women in the present population. A nega-
tive association between sarcopenia and cognitive impair-
ment was also reported in a large British male population.17
Sarcopenia can be prevented or slowed using multidisci-
plinary approaches, including physical exercise and nutri-
tional improvement.30 The usefulness of exercise
intervention for slowing cognitive decline has been exten-
sively demonstrated in the general population, as well as in
dementia patients.31 These findings suggest that sarcopenia
could be a useful target for intervention to prevent cognitive
decline in the elderly population.
There are several limitations to the present study. Al-
though we evaluated two indices of sarcopenia, we did not
measure walking speed. Because slow walking speed is a
component of sarcopenia and frailty, inclusion of walking
speed could further strengthen the interpretation of the find-
ings. The definition of sarcopenia was arbitrary, and accord-
ingly, the absolute cut-off values could be different from
those of other institutes. All of the participants were inde-
pendent in daily life. Accordingly, the findings in the present
study may not be applicable to dependent frail subjects. Fur-
ther studies with subjects with different backgrounds and
ethnicities are necessary to confirm our findings.
In summary, sarcopenic indices, thigh muscle CSA and skel-
etal muscle mass, are modestly but significantly related to ar-
terial stiffness and the presence of WMHs, which could
explain, at least in part, the association between frailty and
cognitive impairment. Sarcopenia may be a useful target for
intervention to prevent not only frailty but also cognitive
impairment.
Acknowledgements
This work was supported in part by Grants-in-Aid for Scien-
tific Research from the Ministry of Education, Culture, Sports,
Science and Technology (no. 25670353 and 16K15419).
564 K. Kohara et al.
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 557–566
DOI: 10.1002/jcsm.12195
The authors certify that they comply with the ethical
guidelines for authorship and publishing of the Journal of Ca-
chexia, Sarcopenia and Muscle.32
Online supplementary material
Additional Supporting Information may be found online in
the supporting information tab for this article.
Table S1. Clinical characteristics of study participants split by
cutoff value of TDAS score in men and women
Table S2. Multiple regression analyses for the Touch Panel-
type Dementia Assessment Scale score in men.
Table S3. Multiple regression analyses for the Touch Panel-
type Dementia Assessment Scale score in women.
Conflict of interest
All authors declare that they have no conflict of interest.
References
1. Robertson DA, Savva GM, Kenny RA. Frailty
and cognitive impairment--a review of the
evidence and causal mechanisms. Ageing
Res Rev 2013;12:840–851.
2. Dodge HH, Mattek NC, Austin D, Hayes TL,
Kaye JA. In-home walking speeds and vari-
ability trajectories associated with mild
cognitive impairment. Neurology
2012;78:1946–1952.
3. Welmer AK, Rizzuto D, Qiu C, Caracciolo B,
Laukka EJ. Walking speed, processing
speed, and dementia: a population-based
longitudinal study. J Gerontol A Biol Sci
Med Sci 2014;69:1503–1510.
4. Ries JD, Echternach JL, Nof L, Gagnon
Blodgett M. Test–retest reliability and min-
imal detectable change scores for the
timed “up & go” test, the six-minute walk
test, and gait speed in people with
Alzheimer disease. Phys Ther 2009;89:
569–579.
5. Verghese J, Ayers E, Barzilai N, Bennett DA,
Buchman AS, Holtzer R, et al. Motoric cog-
nitive risk syndrome: Multicenter incidence
study. Neurology 2014;83:2278–2284.
6. Fried LP, Tangen CM, Walston J, Newman
AB, Hirsch C, Gottdiener J, et al.
Cardiovascular health study collaborative
research group. Frailty in older adults: evi-
dence for a phenotype. J Gerontol Med
Sci 2001;56A:M146–M156.
7. Chen LK, Liu LK, Woo J, Assantachai P,
Auyeung TW, Bahyah KS, et al. Sarcopenia
in Asia: consensus report of the Asian
working group for sarcopenia. J Am Med
Dir Assoc 2014;15:95–101.
8. Abbatecola AM, Chiodini P, Gallo C, Lakatta
E, Sutton-Tyrrell K, Tylavsky FA, et al.
Health ABC study. Pulse wave velocity is as-
sociated with muscle mass decline: Health
ABC study. Age 2012;34:469–478.
9. Ochi M, Kohara K, Tabara Y, Kido T, Uetani
E, Ochi N, et al. Arterial stiffness is associ-
ated with low thigh muscle mass in
middle-aged to elderly men. Atherosclero-
sis 2010;212:327–332.
10. Singer J, Trollor JN, Baune BT, Sachdev PS,
Smith E. Arterial stiffness, the brain and
cognition: a systematic review. Ageing Res
Rev 2014;15:16–27.
11. van Sloten TT, Protogerou AD, Henry RM,
Schram MT, Launer LJ, Stehouwer CD. As-
sociation between arterial stiffness, cere-
bral small vessel disease and cognitive
impairment: A systematic review and
meta-analysis. Neurosci Biobehav Rev
2015;53:121–130.
12. Watfa G, Benetos A, Kearney-Schwartz A,
Labat C, Gautier S, PARTAGE study investi-
gators, et al. Do arterial hemodynamic
parameters predict cognitive decline over
a period of 2 years in individuals older than
80 years living in nursing homes? The
PARTAGE study. J Am Med Dir Assoc
2015;16:598–602.
13. Pase MP, Himali JJ, Beiser A, Maillard P,
Tsao C, et al. Association of aortic stiffness
with cognition and brain aging in young
and middle-aged adults: The Framingham
third generation cohort study. Hyperten-
sion 2016;67:513–519.
14. Prins ND, Scheltens P. White matter
hyperintensities, cognitive impairment
and dementia: an update. Nat Rev Neurol
2015;11:157–165.
15. Nourhashémi F, Andrieu S, Gillette-
Guyonnet S, Reynish E, Albarède JL,
Grandjean H, et al. Is there a relationship
between fat-free soft tissue mass and low
cognitive function? Results from a study
of 7,105 women. J Am Geriatr Soc
2002;50:1796–1801.
16. Abellan van Kan G, Cesari M, Gillette-
Guyonnet S, Dupuy C, Nourhashémi F,
Schott AM, et al. Sarcopenia and cognitive
impairment in elderly women: Results
from the EPIDOS cohort. Age Ageing
2013;42:196–202.
17. Papachristou E, Ramsay SE, Lennon LT,
et al. The relationships between body com-
position characteristics and cognitive
functioning in a population-based sample
of older British men. BMC Geriatr
2015;15:172.
18. Nishiguchi S, Yamada M, Shirooka H, et al.
Sarcopenia as a risk factor for cognitive de-
terioration in community-dwelling older
adults: A 1-year prospective study. J Am
Med Dir Assoc 2016;17:372.e5-8.
19. van Kan GA, Cesari M, Gillette-Guyonnet S,
Dupuy C, Vellas B, Rolland Y. Association of
a 7-year percent change in fat mass and
muscle mass with subsequent cognitive
dysfunction: the EPIDOS-Toulouse cohort.
J Cachexia Sarcopenia Muscle
2013;4:225–229.
20. Ohara M, Kohara K, Tabara Y, Igase M,
Miki T. Portable indices for sarcopenia
are associated with pressure wave
reflection and central pulse pressure: the
J-SHIPP study. J Hypertens
2015;33:314–322.
21. Ohara M, Kohara K, Tabara Y, Ochi M,
Nagai T, Igase M. Sarcopenic obesity
and arterial stiffness, pressure wave
reflection and central pulse pressure:
The J-SHIPP study. Int J Cardiol
2014;174:214–217.
22. Tabara Y, Okada Y, Ohara M, Uetani E, Kido
T, Ochi N, et al. Association of postural
instability with asymptomatic cerebrovas-
cular damage and cognitive decline: The
Japan Shimanami health promoting pro-
gram study. Stroke 2015;46:16–22.
23. A new guideline making committee of
a brain dock. Brain MRI examination.
In Japanese Society for Detection of
Asymptomatic Brain Disease, ed.
Braindock Guideline 2014, 4th ed. Tokyo,
Japan: Kyobunsha; 2014. p 38–47 (In
Japanese).
24. Inoue M, Jinbo D, Nakamura Y, Taniguchi
M, Urakami K. Development and evalua-
tion of a computerized test battery for
Alzheimer’s disease screening in
community-based settings. Am J
Alzheimers Dis Other Demen
2009;24:129–135.
Muscle mass and cognitive impairment 565
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 557–566
DOI: 10.1002/jcsm.12195
25. Tomiyama H, Yamashina A, Araia T, Hirose
K, Koji Y, Chikamori T, et al. Influences of
age and gender on results of noninvasive
brachial–ankle pulse wave velocity mea-
surement—a survey of 12 517 subjects.
Atherosclerosis 2003;166:303–309.
26. Mehrabian S, Duron E, Labouree F, Rollot F,
Bune A, Traykov L, et al. Relationship be-
tween orthostatic hypotension and cogni-
tive impairment in the elderly. J Neurol
Sci 2010;299:45–48.
27. Rockwood K, Fox RA, Stolee P, Robertson
D, Beattie BL. Frailty in elderly people: an
evolving concept. CMAJ
1994;150:489–495.
28. Kelaiditi E, Cesari M, Canevelli M, van Kan
GA, Ousset PJ, Gillette-Guyonnet S, et al.
IANA/IAGG. Cognitive frailty: Rational and
definition from an (I.A.N.A./I.A.G.G.) inter-
national consensus group. J Nutr Health
Aging 2013;17:726–734.
29. Kohara K. Sarcopenic obesity in aging popu-
lation: current status and future directions
for research. Endocrine 2014;45:15–25.
30. Cruz-Jentoft AJ, Landi F, Schneider SM,
et al. Prevalence of and interventions for
sarcopenia in ageing adults: a systematic
review. Report of the International
Sarcopenia Initiative (EWGSOP and IWGS).
Age Ageing 2014;43:748–759.
31. Forbes D, Thiessen EJ, Blake CM, Forbes SC,
Forbes S. Exercise programs for people
with dementia. Cochrane Database Syst
Rev 2013;12:CD006489.
32. von Haehling S, Morley JE, Coats AJS, Anker
SD. Ethical guidelines for publishing in the
Journal of Cachexia, Sarcopenia and
Muscle: update 2015. J Cachexia
Sarcopenia Muscle 2015;6:315-6.
566 K. Kohara et al.
Journal of Cachexia, Sarcopenia and Muscle 2017; 8: 557–566
DOI: 10.1002/jcsm.12195
